$15 M IPO: Inflammatory Disease Biotech Curanex Launches on Nasdaq with Botanical Focus

Curanex Pharmaceuticals (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has successfully completed its Initial Public Offering (IPO). The company raised $15 million in gross proceeds through the offering of 3,750,000 shares at $4.00 per share.

Trading of CURX shares commenced on the Nasdaq Capital Market on August 26, 2025. The underwriters, led by Dominari Securities LLC, have a 45-day option to purchase up to 562,500 additional shares at the public offering price, less underwriting discounts and expenses.

https://www.stocktitan.net/news/CURX/curanex-pharmaceuticals-inc-announces-closing-of-its-initial-public-pu072jo6qwxe.html